Drug Use-Results Survey on Picoprep® Combination Powder

Completed

• Conditions: Bowel Cleansing
• Interventions: Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid

• Registration Number: NCT03631446
• Lead Sponsor: Ferring Pharmaceuticals

Brief Summary

The purpose of this survey is to confirm safety and efficacy with patients who are administered the Picoprep® for cleansing of intestinal contents for preparation of colonoscopy and colorectal surgery.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-29
• Study First Submitted: 2018-08-13
• Study First Submitted QC: 2018-08-13
• Study First Posted: 2018-08-15
• Status Verified: 2021-10
• Primary Completion: 2021-12-31
• Study Completion: 2021-12-31
• Last Update Submitted: 2022-01-14
• Last Update Posted: 2022-01-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1298

Inclusion Criteria

Patients who are administered the Picoprep® for cleansing of intestinal contents for preparation of colonoscopy and colorectal surgery.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients administered Picoprep® for bowel cleansing	Sodium Picosulfate, Magnesium Oxide and Citric Acid	Patients administered Sodium Picosulfate, Magnesium Oxide and Citric Acid for bowel cleansing

Primary Outcome Measures

Name	Time	Method
Bowel cleansing assessment for colonoscopy	48 hours after drug administration	Assessment of each part of large intestine using a bowel cleanliness rating scale
Bowel cleansing assessment for colorectal surgery	48 hours after drug administration	Assessment of each part of large intestine using a bowel cleanliness rating scale

Trial Locations

Locations (1)

Investigational Site (there may be other sites in this country); 🇯🇵 Shibuya, Tokyo, Japan